Pfizer has announced it will provide its breast cancer drug, palbociclib — which has been provisionally rejected by NICE for routine use as a result of cost — to the
Pfizer has announced it will provide its breast cancer drug, palbociclib — which has been provisionally rejected by NICE for routine use as a result of cost — to the